ArticleFrontiers in endocrinology2025
Clinical study status of diabetic gastrointestinal diseases.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bridging the gap from mechanism to clinic: a translational perspective on taVNS for gastrointestinal disorders.Frontiers in neuroscience · 2026Review
- Differential Effects of Losartan and Finerenone on Diabetic Remodeling, Oxidative Stress and ACE Activity in the Gastrointestinal Tract of Streptozotocin-Induced Diabetic Rats.International journal of molecular sciences · 2025Article
- Methodological panorama of clinical trials for diabetic foot ulcers: a scope review of design, implementation and reporting.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic gastrointestinal diseases not only affect the quality of life of patients, but also bring heavy economic burden to patients. Understanding of the current features of diabetic gastrointestinal diseases-related clinical trials are important for improving designs of clinical trials and identifying neglected areas of study. Despite the high prevalence of gastrointestinal complications among diabetic patients, comprehensive analyses of registered clinical trials are lacking. This study aimed to present a scoping overview of diabetic gastrointestinal diseases-related clinical trials registered in ClinicalTrials.gov, ChiCTR and high-quality diabetic gastrointestinal diseases-related clinical trials published in Pubmed in the past 10 years. Methods: The trials registered in ClinicalTrials.gov and ChiCTR databases from the establishment of the database to June 14,2024 were searched. Moreover, high-quality trials with impact factors of 5 points or more published in Pubmed from June 2014 to June 2024 were searched. The results were extracted and presented in tabular form. Results: Most studies focused on diabetic gastroparesis, with drug interventions being the most common. In addition, most studies were small sample sizes (≤100), randomized parallel controlled trials and 69.01% of the studies used different methods of blinding. Most studies did not conduct safety evaluation and follow-up. Conclusion: The diagnostic criteria of diabetic gastrointestinal diseases were diverse. Furthermore, most studies on diabetic gastrointestinal diseases focused on diabetic gastroparesis. There was considerable heterogeneity in study designs and efficacy evaluations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.